News | June 08, 2012

Boston Scientific Increases Longevity Projections for Its U.S. Defibrillators

June 8, 2012 — The U.S. Food and Drug Administration (FDA) has approved revised product labeling for Boston Scientific Corp.’s Incepta, Energen, Punctua, Cognis and Teligen implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds), to reflect increased longevity projections for these devices. The longevity projections are based on data submitted to the FDA and vary for each device dependent on the model type and settings.

Projected device longevity exceeds 10 years for some models of Boston Scientific ICDs and approaches eight years for its CRT-D devices. The company backs these devices with warranties of up to 10 years* in the U.S. and many other international markets. Depending on the model, the device warranties are also up to twice as long as other currently marketed comparable devices.

"We're pleased with the new labeling for our U.S. defibrillator products which provides doctors and patients with additional assurance about the longevity and reliability of these devices," said Kenneth Stein, M.D., chief medical officer of Boston Scientific's Cardiac Rhythm Management Group. "Boston Scientific ICDs and CRT-Ds benefit from our proprietary advanced battery technology. The new battery was first introduced in the Cognis and Teligen devices in 2008 and has now been incorporated into our newest devices with up to a 10-year warranty."

"The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) long-term follow-up study results, which were recently presented at the Heart Rhythm Society annual meeting in Boston, demonstrates that ICD therapy continues to benefit patients for a median follow-up of 11 years. Particularly in Class II patients, it appears that an ICD may prolong a patient's life for at least a decade by rescuing the patient from sudden cardiac death," said Jeanne Poole, M.D., director, Arrhythmia Service and Electrophysiology Laboratory at the University of Washington Medical Center in Seattle.

"By helping to mitigate the frequency of replacing an ICD or CRT-D device, this technology provides us with the potential to reduce the complications associated with replacement procedures and to reduce healthcare costs. Not only does the patient benefit from fewer surgeries, but the financial benefit can be significant," said Poole.

For more information: www.bostonscientific.com

* Incepta and Energen VR ICD: 10 years; Incept and Energen DR ICD: 8 years; Punctua and Teligen ICD: 7 years; Incepta and Energen CRT-D: 6 years; Punctua and Cognis CRT-D: 5 years.

Related Content

The global, prospective, non-randomized UNTOUCHED study evaluated the safety and efficacy of the Boston Scientific Emblem S-ICD System – the only approved implantable defibrillator without wires touching the heart –  for primary prevention of sudden cardiac death specifically in patients with a left ventricular ejection fraction (LVEF) ≤35 percent, the most common population to be indicated for ICD therapy. #Heartrhythm2020 #HRS20 #HRS2020
News | Implantable Cardioverter Defibrillator (ICD) | May 08, 2020
May 8, 2020 — Final results from the UNTOUCHED study of the Emblem Subcutaneous Implantable Defibrillator (S-ICD) Sys
The Boston Scientific Emblem MRI-safe S-ICD system does not require a transvenous lead, leading to fewer complications with this type of ICD.

The Boston Scientific Emblem MRI-safe S-ICD system does not require a transvenous lead, leading to fewer complications with this type of ICD.

Feature | Implantable Cardioverter Defibrillator (ICD) | May 08, 2020
May 8, 2020 — A new clinical trial is the first to compare the safety and efficacy of subcutaneous implantable cardio
Medtronic Initiates Worldwide Pivotal Study of Extravascular Implantable Cardioverter Defibrillator
News | Implantable Cardioverter Defibrillator (ICD) | October 11, 2019
Medtronic plc announced the start of a worldwide pivotal study evaluating its investigational Extravascular Implantable...
Early ICD Use Prolongs Survival After Coronary Stenting
News | Implantable Cardioverter Defibrillator (ICD) | September 18, 2019
Early use of an implantable cardioverter-defibrillator (ICD) after primary coronary intervention lengthens survival in...
A physician explaining an implantable cardioverter defibrillator (ICD) to a patient. Image courtesy of Biotronik.

A physician explaining an implantable cardioverter defibrillator (ICD) to a patient. Image courtesy of Biotronik.

Feature | Implantable Cardioverter Defibrillator (ICD) | May 24, 2019 | Dave Fornell, Editor
This is a brief overview of updates on...
Emblem Subcutaneous ICD Safe and Effective for Majority of Patients
News | Implantable Cardioverter Defibrillator (ICD) | May 13, 2019
May 13, 2019 — Boston Scientific announced acute results from the UNTOUCHED study evaluating safety and efficacy of t
Medtronic Begins Pilot Study of Investigational Extravascular ICD System
News | Implantable Cardioverter Defibrillator (ICD) | August 09, 2018
Medtronic plc announced the start of a pilot study of its investigational Extravascular Implantable Cardioverter...
ICD Placements Not Meeting Medicare Coverage Criteria Decline After Overuse Investigation Announced
Feature | Implantable Cardioverter Defibrillator (ICD) | July 11, 2018
Placement of implantable cardioverter defibrillators (ICDs) not meeting Centers for Medicare and Medicaid Services (CMS...
New Tool Predicts Benefits and Risks of Implantable Defibrillator for Heart Failure Patients
News | Implantable Cardioverter Defibrillator (ICD) | July 02, 2018
University of Washington (UW) Medicine cardiologists have developed a tool to predict which heart-failure patients...
Real-World Data Demonstrates Success Of Smart Pass Filter on Boston Scientific S-ICD System
News | Implantable Cardioverter Defibrillator (ICD) | May 16, 2018
Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful reduction of...